FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2253974734> ?p ?o ?g. }

• W2253974734 endingPage "3904" @default.
• W2253974734 startingPage "3897" @default.
• W2253974734 abstract "// Martina Kluth 1, * , David Meyer 1, * , Antje Krohn 1 , Fabian Freudenthaler 1 , Melanie Bauer 1 , Georg Salomon 2 , Hans Heinzer 2 , Uwe Michl 2 , Stefan Steurer 1 , Ronald Simon 1 , Guido Sauter 1 , Thorsten Schlomm 2, 3 , Sarah Minner 1 1 Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 2 Prostate Cancer Center, Martini-Clinic, Hamburg, Germany 3 Department of Urology, Section for Translational Prostate Cancer Research at University Medical Center Hamburg-Eppendorf, Hamburg, Germany * These authors contributed equally to this work Correspondence to: Ronald Simon, e-mail: r.simon@uke.de Keywords: 6q deletion, prostate cancer, ERG, MAP3K7, heterogeneity Received: August 27, 2015      Accepted: November 22, 2015      Published: December 14, 2015 ABSTRACT Prostate cancer is notorious for its heterogeneity, which poses a problem for the applicability of diagnostic molecular markers. However, heterogeneity analysis can provide valuable information on the chronology in which molecular alterations arise. Here, we constructed a heterogeneity tissue microarray (TMA) comprising samples from 10 different tumor areas of 189 prostate cancers each in order to study the sequence of two frequent molecular alterations, i.e. 6q15 deletion and TMPRSS2:ERG fusion. Previous work shows a marked inverse relationship between these alterations, suggesting that presence of one of these alterations might impact development of the other. 6q15 deletion was analyzed by fluorescence in situ hybridization and ERG-expression by immunohistochemistry. Only 6.6% of 334 ERG-positive but 28.4% of 440 ERG-negative TMA spots showed 6q15 deletions ( p < 0.0001). A breakdown of these data to the level of tumor foci revealed 6q deletions in 138 tumor foci that were large enough to have at least 3 analyzable TMA spots. These included 42 tumor foci with homogeneous ERG positivity and 16 with homogeneous 6q15 deletions. Remarkably, six of the 42 homogeneously ERG -positive tumor foci (14.3%) harbored small 6q15-deleted areas, but none of the 34 6q15-deleted foci showed areas of ERG positivity ( p = 0.022). In conclusion, our data suggest that ERG -fusion can precede 6q15 deletion, but not vice versa. The complete absence of ERG-positive tumor areas in 6q15-deleted tumor foci further suggest that the functional consequences of 6q15 deletions may prevent the development of TMPRSS2:ERG fusions." @default.
• W2253974734 created "2016-06-24" @default.
• W2253974734 creator A5002278969 @default.
• W2253974734 creator A5020417501 @default.
• W2253974734 creator A5021421424 @default.
• W2253974734 creator A5024801599 @default.
• W2253974734 creator A5027594836 @default.
• W2253974734 creator A5031507153 @default.
• W2253974734 creator A5048594167 @default.
• W2253974734 creator A5049914905 @default.
• W2253974734 creator A5059639992 @default.
• W2253974734 creator A5060519896 @default.
• W2253974734 creator A5074342534 @default.
• W2253974734 creator A5086499788 @default.
• W2253974734 creator A5090488652 @default.
• W2253974734 date "2015-12-14" @default.
• W2253974734 modified "2023-09-24" @default.
• W2253974734 title "Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer" @default.
• W2253974734 cites W1508389343 @default.
• W2253974734 cites W1770022775 @default.
• W2253974734 cites W1966230453 @default.
• W2253974734 cites W1969947723 @default.
• W2253974734 cites W1988336550 @default.
• W2253974734 cites W2003579067 @default.
• W2253974734 cites W2005841299 @default.
• W2253974734 cites W2017329417 @default.
• W2253974734 cites W2018825948 @default.
• W2253974734 cites W2022008236 @default.
• W2253974734 cites W2022093187 @default.
• W2253974734 cites W2027845674 @default.
• W2253974734 cites W2050517163 @default.
• W2253974734 cites W2054074987 @default.
• W2253974734 cites W2056476264 @default.
• W2253974734 cites W2071120462 @default.
• W2253974734 cites W2076485183 @default.
• W2253974734 cites W2077957240 @default.
• W2253974734 cites W2091481108 @default.
• W2253974734 cites W2107633226 @default.
• W2253974734 cites W2109042735 @default.
• W2253974734 cites W2121158863 @default.
• W2253974734 cites W2124907227 @default.
• W2253974734 cites W2135757180 @default.
• W2253974734 cites W2147489040 @default.
• W2253974734 cites W2149848093 @default.
• W2253974734 cites W2159715390 @default.
• W2253974734 cites W2170233852 @default.
• W2253974734 cites W2172123503 @default.
• W2253974734 cites W2323868208 @default.
• W2253974734 cites W4211195653 @default.
• W2253974734 doi "https://doi.org/10.18632/oncotarget.6597" @default.
• W2253974734 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4826178" @default.
• W2253974734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26684029" @default.
• W2253974734 hasPublicationYear "2015" @default.
• W2253974734 type Work @default.
• W2253974734 sameAs 2253974734 @default.
• W2253974734 citedByCount "8" @default.
• W2253974734 countsByYear W22539747342018 @default.
• W2253974734 countsByYear W22539747342019 @default.
• W2253974734 countsByYear W22539747342020 @default.
• W2253974734 countsByYear W22539747342021 @default.
• W2253974734 countsByYear W22539747342022 @default.
• W2253974734 countsByYear W22539747342023 @default.
• W2253974734 crossrefType "journal-article" @default.
• W2253974734 hasAuthorship W2253974734A5002278969 @default.
• W2253974734 hasAuthorship W2253974734A5020417501 @default.
• W2253974734 hasAuthorship W2253974734A5021421424 @default.
• W2253974734 hasAuthorship W2253974734A5024801599 @default.
• W2253974734 hasAuthorship W2253974734A5027594836 @default.
• W2253974734 hasAuthorship W2253974734A5031507153 @default.
• W2253974734 hasAuthorship W2253974734A5048594167 @default.
• W2253974734 hasAuthorship W2253974734A5049914905 @default.
• W2253974734 hasAuthorship W2253974734A5059639992 @default.
• W2253974734 hasAuthorship W2253974734A5060519896 @default.
• W2253974734 hasAuthorship W2253974734A5074342534 @default.
• W2253974734 hasAuthorship W2253974734A5086499788 @default.
• W2253974734 hasAuthorship W2253974734A5090488652 @default.
• W2253974734 hasBestOaLocation W22539747341 @default.
• W2253974734 hasConcept C103796816 @default.
• W2253974734 hasConcept C118487528 @default.
• W2253974734 hasConcept C121608353 @default.
• W2253974734 hasConcept C126322002 @default.
• W2253974734 hasConcept C142724271 @default.
• W2253974734 hasConcept C193270364 @default.
• W2253974734 hasConcept C2776235491 @default.
• W2253974734 hasConcept C2778042024 @default.
• W2253974734 hasConcept C2779134260 @default.
• W2253974734 hasConcept C2780192828 @default.
• W2253974734 hasConcept C2780827179 @default.
• W2253974734 hasConcept C3008058167 @default.
• W2253974734 hasConcept C524204448 @default.
• W2253974734 hasConcept C71924100 @default.
• W2253974734 hasConceptScore W2253974734C103796816 @default.
• W2253974734 hasConceptScore W2253974734C118487528 @default.
• W2253974734 hasConceptScore W2253974734C121608353 @default.
• W2253974734 hasConceptScore W2253974734C126322002 @default.
• W2253974734 hasConceptScore W2253974734C142724271 @default.
• W2253974734 hasConceptScore W2253974734C193270364 @default.
• W2253974734 hasConceptScore W2253974734C2776235491 @default.

• next